A <scp>P</scp>hase 2 study of <scp>L</scp>‐asparaginase encapsulated in erythrocytes in elderly patients with <scp>P</scp>hiladelphia chromosome negative acute lymphoblastic leukemia: The <scp>GRASPALL/GRAALL‐SA</scp>2‐2008 study

Abstract

The addition of GRASPA®, especially at the 100 IU/kg dose level, is feasible in elderly patients without excessive toxicity and associated with durable asparagine depletion. (clinicaltrials.gov identifier NCT01523782).